Wedbush raised the firm’s price target on Tourmaline Bio (TRML) to $43 from $42 and keeps an Outperform rating on the shares. All key ...
John WoodsideLocal Journalism Initiative ReporterCanada's National ObserverEconomic uncertainty may be building as the threat of a full-blown trade war &nbs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback